SG/CALL/VERTEX PHARMACEUTICALS/300/0.1/21.06.24 | Market Closed - Deutsche Boerse AG 10:01:47 13/06/2024 pm IST | ||
| 16.67 EUR | +3.03% |
|
| Current month | +17.23% | ||
| 1 month | +36.98% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 13/24/13 | 16.67 | +3.03% |
| 12/24/12 | 16.18 | -4.66% |
| 11/24/11 | 16.97 | -1.11% |
| 10/24/10 | 17.16 | +0.41% |
| 07/24/07 | 17.09 | +0.59% |
Delayed Quote Deutsche Boerse AG
Last update June 13, 2024 at 10:01 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SQ4HDN |
| ISIN | DE000SQ4HDN3 |
| Date issued | 16/11/2022 |
| Strike | 300 $ |
| Maturity | 21/06/2024 (6 Days) |
| Parity | 10 : 1 |
| Emission price | 7.09 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 17.19 € |
|---|---|
| Lowest since issue | 4.2 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Warrants
- Warrant
